Health Care • Biotechnology: Pharmaceutical Preparations
$3.86 ▼ -0.09
(-2.28%)
MKT CAP: $38.4M • VOL: 133.5K
52W L $4 52W H $9
ROARABLE / RQD
E • 34/100
PIOTROSKI
4 / 9
SCYX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $20.6M | $3.7M | $140.1M |
| YoY Revenue Growth % | +449.9% | -97.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$16.1M | -$37.1M | $72.7M |
| Operating Margin % | -78.0% | -80.0% | 51.9% |
| Net Income (GAAP) | -$8.6M | -$21.3M | $67.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.3M | -$24.0M | $60.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$5.3M | -$24.0M | $60.2M |
| FCF Margin % | -25.6% | -80.0% | 42.9% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $21.3M | $16.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $49.4M | $55.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SCYX.